290.23
price down icon0.22%   -0.9291
 
loading
前日終値:
$291.16
開ける:
$288.93
24時間の取引高:
841.79K
Relative Volume:
0.38
時価総額:
$156.24B
収益:
$34.76B
当期純損益:
$6.62B
株価収益率:
23.74
EPS:
12.223
ネットキャッシュフロー:
$10.61B
1週間 パフォーマンス:
-3.53%
1か月 パフォーマンス:
+6.43%
6か月 パフォーマンス:
+2.62%
1年 パフォーマンス:
-8.40%
1日の値動き範囲:
Value
$288.26
$292.63
1週間の範囲:
Value
$288.26
$302.81
52週間の値動き範囲:
Value
$253.30
$335.88

Amgen Inc Stock (AMGN) Company Profile

Name
名前
Amgen Inc
Name
セクター
Healthcare (1144)
Name
電話
(805)447-1000
Name
住所
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Name
職員
28,000
Name
Twitter
@amgen
Name
次回の収益日
2025-02-04
Name
最新のSEC提出書
Name
AMGN's Discussions on Twitter

AMGN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
AMGN
Amgen Inc
290.21 156.75B 34.76B 6.62B 10.61B 12.22
Drug Manufacturers - General icon
LLY
Lilly Eli Co
814.22 740.84B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
187.13 458.49B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
227.23 402.83B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
123.73 250.00B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
87.07 219.80B 63.43B 16.42B 14.72B 6.4861

Amgen Inc Stock (AMGN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-09-03 再開されました Raymond James Mkt Perform
2025-05-20 再開されました Guggenheim Neutral
2025-04-22 再開されました Cantor Fitzgerald Neutral
2024-12-10 再開されました BofA Securities Underperform
2024-11-15 開始されました Wolfe Research Peer Perform
2024-11-14 開始されました Citigroup Neutral
2024-10-17 開始されました Bernstein Outperform
2024-10-14 ダウングレード Truist Buy → Hold
2024-09-27 開始されました Cantor Fitzgerald Overweight
2024-08-07 ダウングレード Wells Fargo Overweight → Equal Weight
2024-05-03 アップグレード Barclays Underweight → Equal Weight
2024-05-03 アップグレード William Blair Mkt Perform → Outperform
2024-03-28 再開されました Raymond James Mkt Perform
2024-02-07 ダウングレード Leerink Partners Outperform → Market Perform
2023-12-21 アップグレード Daiwa Securities Neutral → Buy
2023-12-19 アップグレード BMO Capital Markets Market Perform → Outperform
2023-12-12 アップグレード RBC Capital Mkts Sector Perform → Outperform
2023-11-09 開始されました Deutsche Bank Hold
2023-11-02 アップグレード Truist Hold → Buy
2023-10-20 再開されました JP Morgan Neutral
2023-10-17 再開されました Morgan Stanley Equal-Weight
2023-10-11 再開されました BofA Securities Neutral
2023-09-06 開始されました HSBC Securities Buy
2023-04-24 繰り返されました Oppenheimer Outperform
2023-03-13 アップグレード Wells Fargo Equal Weight → Overweight
2023-02-13 繰り返されました Truist Buy
2022-11-18 開始されました Credit Suisse Underperform
2022-10-31 ダウングレード Barclays Equal Weight → Underweight
2022-10-11 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-05-23 開始されました SVB Leerink Mkt Perform
2022-02-09 繰り返されました Barclays Equal Weight
2022-02-09 繰り返されました Jefferies Buy
2022-02-09 繰り返されました Morgan Stanley Equal-Weight
2022-02-09 繰り返されました Oppenheimer Outperform
2022-02-09 繰り返されました Wells Fargo Equal Weight
2022-01-05 ダウングレード BofA Securities Buy → Neutral
2021-12-09 再開されました Wells Fargo Equal Weight
2021-12-06 開始されました Goldman Buy
2021-11-19 開始されました BMO Capital Markets Market Perform
2021-09-23 ダウングレード Daiwa Securities Outperform → Neutral
2021-09-07 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-12-29 開始されました Daiwa Securities Buy
2020-10-28 開始されました UBS Neutral
2020-10-26 アップグレード Raymond James Mkt Perform → Outperform
2020-10-12 アップグレード Truist Hold → Buy
2020-10-09 ダウングレード Bernstein Outperform → Mkt Perform
2020-10-09 ダウングレード Truist Buy → Hold
2020-10-08 ダウングレード Raymond James Outperform → Mkt Perform
2020-04-15 再開されました Guggenheim Neutral
2020-03-31 開始されました Wolfe Research Peer Perform
2020-03-30 アップグレード Raymond James Mkt Perform → Outperform
2020-03-05 アップグレード BofA/Merrill Neutral → Buy
2020-02-27 開始されました Barclays Equal Weight
2020-01-31 ダウングレード Robert W. Baird Neutral → Underperform
2020-01-21 アップグレード Evercore ISI In-line → Outperform
2019-12-24 開始されました Raymond James Mkt Perform
2019-12-17 再開されました Morgan Stanley Overweight
2019-11-12 開始されました SunTrust Buy
2019-11-05 アップグレード Cantor Fitzgerald Neutral → Overweight
2019-10-17 再開されました BofA/Merrill Neutral
2019-08-19 ダウングレード Mizuho Buy → Neutral
2019-05-23 アップグレード Citigroup Neutral → Buy
すべてを表示

Amgen Inc (AMGN) 最新ニュース

pulisher
07:49 AM

Does Amgen Inc. fit your quant trading modelTrade Exit Summary & Verified Chart Pattern Trade Signals - newser.com

07:49 AM
pulisher
07:12 AM

How supply shortages influence Amgen Inc. (AMG) stock2025 Dividend Review & Verified Entry Point Signals - newser.com

07:12 AM
pulisher
06:47 AM

Trust Investment Advisors Increases Stock Holdings in Amgen Inc. $AMGN - MarketBeat

06:47 AM
pulisher
06:46 AM

Howard Capital Management Inc. Has $5.86 Million Stock Position in Amgen Inc. $AMGN - MarketBeat

06:46 AM
pulisher
06:17 AM

Motley Fool Asset Management LLC Acquires 2,924 Shares of Amgen Inc. $AMGN - MarketBeat

06:17 AM
pulisher
06:07 AM

Logan Capital Management Inc. Reduces Holdings in Amgen Inc. $AMGN - MarketBeat

06:07 AM
pulisher
06:07 AM

Fjarde AP Fonden Fourth Swedish National Pension Fund Has $30.26 Million Position in Amgen Inc. $AMGN - MarketBeat

06:07 AM
pulisher
05:25 AM

Will Amgen Inc. (AMG0) stock extend growth storyWeekly Volume Report & Technical Analysis for Trade Confirmation - newser.com

05:25 AM
pulisher
05:18 AM

Teacher Retirement System of Texas Sells 8,974 Shares of Amgen Inc. $AMGN - MarketBeat

05:18 AM
pulisher
05:08 AM

Transcend Capital Advisors LLC Decreases Stake in Amgen Inc. $AMGN - MarketBeat

05:08 AM
pulisher
04:28 AM

Should I buy Amgen Inc. (AMG0) stock before earnings seasonWeekly Trade Review & Daily Chart Pattern Signal Reports - newser.com

04:28 AM
pulisher
03:39 AM

What Fibonacci levels say about Amgen Inc. rebound2025 Valuation Update & Fast Exit and Entry Trade Guides - newser.com

03:39 AM
pulisher
02:38 AM

Is Amgen Inc. (AMG) stock protected from inflationQuarterly Growth Report & Community Driven Trade Alerts - newser.com

02:38 AM
pulisher
02:12 AM

Amgen (AMGN) Expected to Announce Earnings on Tuesday - MarketBeat

02:12 AM
pulisher
01:34 AM

Why Amgen Inc. (AMG) stock could be top winnerNew Guidance & Weekly Breakout Opportunity Watchlist - Fundação Cultural do Pará

01:34 AM
pulisher
01:09 AM

Using flow based indicators on Amgen Inc.2025 Support & Resistance & Growth Focused Stock Pick Reports - newser.com

01:09 AM
pulisher
01:09 AM

What dividend safety score for Amgen Inc. stockEarnings Growth Report & Free Community Consensus Stock Picks - newser.com

01:09 AM
pulisher
12:52 PM

What is the fair value estimate for Amgen Inc. (AMG) stock in 2025Weekly Profit Summary & Fast Gain Stock Tips - newser.com

12:52 PM
pulisher
12:42 PM

Will Amgen Inc. (AMG0) stock profit from AI boom2025 Market Sentiment & AI Forecast Swing Trade Picks - newser.com

12:42 PM
pulisher
12:32 PM

Will Amgen Inc. (AMG0) stock recover faster than industry2025 Trading Recap & Real-Time Chart Pattern Alerts - newser.com

12:32 PM
pulisher
Oct 27, 2025

Amgen’s Promising Phase 3 Study on Blinatumomab for Leukemia: What Investors Need to Know - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s Long-term Study on Dazodalibep: A Potential Breakthrough for Sjögren’s Syndrome - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s Phase 2a Study on Autoimmune Diseases: A Potential Game-Changer? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s Apremilast Study: A Potential Game-Changer for Pediatric Behçet’s Disease - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s CodeBreaK 202: A New Frontier in Lung Cancer Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s Innovative Study on AMG 193: A Potential Game-Changer in Cancer Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen Inc. stock daily chart insights2025 Big Picture & Technical Confirmation Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s AMG 509 Study: A Potential Game-Changer in Prostate Cancer Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s Romiplostim Study: A Potential Game-Changer for Cancer Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s Latest Clinical Study Update: A New Hope for Small Cell Lung Cancer? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s Apremilast Study: A New Hope for Pediatric Patients - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s New Prostate Cancer Study: A Potential Game-Changer? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s Phase 3 Study on Xaluritamig: A Potential Game-Changer in Prostate Cancer Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s New Study on Xaluritamig: A Potential Game-Changer in Prostate Cancer Treatment? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s Prolia Study: A New Horizon for Male Osteoporosis Treatment in China - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s Promising Study on Romosozumab for Osteogenesis Imperfecta: A Potential Game-Changer - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s AMG 355 Study: A Potential Game-Changer in Oncology? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s Promising Phase 3 Study on Metastatic Colorectal Cancer - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s Phase 2 Study on Tarlatamab: A Potential Game-Changer for SCLC Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s Pediatric NMOSD Study: A Potential Game-Changer? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s Maridebart Cafraglutide: A New Hope for Cardiovascular Health? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s Repatha® Study: A Potential Game-Changer in Cardiovascular Care - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s Latest Clinical Study: A Potential Game-Changer in Lung Cancer Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s AMG 193 Study: A Potential Game-Changer in Thoracic Tumor Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s Prolia® Study: A New Frontier in Osteoporosis Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s Sotorasib Study: A Real-World Evaluation in Chinese NSCLC Patients - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s Phase 3 Study on Rocatinlimab: A Potential Game-Changer for Prurigo Nodularis - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s New Diabetes Study: A Potential Game-Changer? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s Pediatric Psoriasis Study: A Potential Game-Changer in Dermatology - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s Latest Study: A New Contender in Lung Cancer Treatment? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Amgen’s AMG 193 Study: A New Hope for Advanced NSCLC Treatment? - TipRanks

Oct 27, 2025

Amgen Inc (AMGN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$118.25
price down icon 1.76%
drug_manufacturers_general PFE
$24.51
price down icon 1.05%
drug_manufacturers_general NVO
$51.97
price down icon 1.73%
drug_manufacturers_general SNY
$50.74
price down icon 1.34%
drug_manufacturers_general MRK
$87.04
price down icon 1.07%
大文字化:     |  ボリューム (24 時間):